Toward More Uniform Methotrexate Dosing in Psoriasis International expert group urges common standards Mar 30, 2022
Jada Pinkett Smith's Alopecia The condition at the center of this year's Academy Awards drama Mar 29, 2022
Significant Improvement in Vitiligo With JAK Inhibitor Therapy Durable improvement in pigmentation with topical ruxolitinib, oral ritlecitinib Mar 29, 2022
Atopic Dermatitis: Promising Data for New Mechanistic Approach Rapid responses in a majority of patients in small trial of eblasakimab Mar 28, 2022
Targeted Antibody Provides Significant Relief From Itchy Nodular Condition Dupilumab reduces itch, lesion count in first phase III trial for prurigo nodularis Mar 28, 2022
Dramatic, Durable Hair Growth With Oral JAK Inhibitor Oral baricitinib superior to placebo at 36 weeks in BRAVE-AA1 and BRAVE-AA2 trials Mar 27, 2022
Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
Clinic-Based Hidradenitis Suppurativa Surgery Gets High Marks From Patients High satisfaction after three-fourths of procedures, despite frequent recurrences Mar 17, 2022
Extension Study Confirms JAK Inhibitor's Activity in Atopic Dermatitis EASI75 response rate exceeding 80% through 52 weeks of upadacitinib treatment Mar 16, 2022
FDA Warns on Using Surgical Device for Aesthetic Skin Procedures Agency details potentially life-threatening adverse events with plasma-generating device Mar 14, 2022
Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
Predicting Treatment Response in Inflammatory Muscle Disorders Swedish registry study elicits factors associated with improvement Feb 16, 2022
Acute Muscle Weakness and Skin Rash Following a Lupus Diagnosis Clinicians consider many differentials Feb 14, 2022
Two Years On, Tremfya Still Shines in Psoriatic Arthritis Efficacy increases in long-term extension data Feb 10, 2022
Hair Loss Drugs Ranked in Order of Efficacy Meta-analysis attempts a head-to-head comparison Feb 07, 2022
Evidence Begins to Gel for Atopic Dermatitis, Multiple Comorbid Conditions Atopic, metabolic, cardiovascular, and mental health conditions cited in guideline update Feb 02, 2022
Psoriasis Patients, Docs Want to Do More to Prevent Heart Problems Despite well-known cardiovascular risks, most patients currently undertreated Jan 19, 2022
FDA OKs Two Oral JAK Inhibitors for Refractory Atopic Dermatitis Once-daily abrocitinib and upadacitinib join topical ruxolitinib in expanding AD market Jan 18, 2022
Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
IL-13 Inhibitor Approved for Adults With Atopic Dermatitis Significantly greater lesion clearance with tralokinumab in placebo-controlled studies Dec 28, 2021
Doc Fired After Standing Up to Private Equity; RFK Jr.'s Anti-Vax Machine This past week in healthcare investigations Dec 22, 2021
Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
Think TikTok Is Smarter Than Me? Then I'm Not the Right Doctor for You Modern times have fundamentally altered the landscape of healthcare Nov 30, 2021
Signs of Relief From 'Therapeutic Drought' in Atopic Dermatitis Encouraging results from pipeline agents targeting Th2-specific inflammation Nov 09, 2021
Could This Biologic Drug Work in Patients Lacking Its Target? Bizarre finding with omalizumab Nov 07, 2021
Dramatic Responses in Cutaneous Sarcoidosis With JAK Inhibitor More than 80% reduction in disease activity in case series of tofacitinib treatment Nov 07, 2021
Substantial Improvement in Vitiligo With Topical JAK Inhibitor About 30% of patients had 75% clearance after 6 months, half had 50% clearance Nov 06, 2021
Early Success With New Target in Atopic Dermatitis Inhibition of Th2-related inflammation leads to rapid improvement in disease activity Nov 05, 2021
Topical PDE4 Inhibitor Impresses in Trial of Seborrheic Dermatitis Rapid, persistent improvement in body surface area, itch, other symptoms with roflumilast Nov 04, 2021
How Should Patients With Autoimmune Diseases Approach COVID Vaccination? Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
Botox Doc's License Suspended Over Breast, Penis Enhancement Harms One patient allegedly required two surgeries to fix penile enhancement gone wrong Oct 21, 2021
FDA to Make Isotretinoin Prescribing Gender Neutral Revision to risk management program dissociates gender from reproductive categories Oct 18, 2021
Is Private Equity a Dangerous Employer? Firms' investments in healthcare continue to expand, at what cost? Oct 14, 2021
Case: VEGFR Inhibition in Merkel Cell Carcinoma Patient Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer Oct 11, 2021
FDA Warns on Needle-Free Injection Devices for Facial Fillers Serious injuries and "irreversible" harm to skin, lips, and eyes reported with unapproved devices Oct 08, 2021